Genmab — Maj 2019

[E_L]

POTENT ANTI-TUMOR ACTIVITY OF DUOBODY-CD3XCD20 IN PRECLINICAL MODELS IN VITRO AND IN VIVO https://learningcenter.ehaweb.org/eha/2019/24th/266918/ida.hiemstra.potent.anti-tumor.activity.of.duobody-cd3xcd20.in.preclinical.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dcd20%2Bcd3

[Bulder]

Cassiopeia præsenteres på Presidential Symposium på EHA

[E_L]

what a day...

[Bulder]

Cassiopeia-kombien bliver THE standard of care MM asct i row.

[Legolas23]

SC i CD3xCD20 lover også godt. Bliver spændende at følge.

[Helge_LarsenPI-redaktør]

Luk i dagens højeste.

[Bella1]

Tager også lige en aftenpürsch, - det ka`ikke gå galt på sådan en dag

[Sukkeralf]

http://ir.exelixis.com/news-releases/news-release-details/exelixis-and-iconic-therapeutics-enter-exclusive-option-and

[Sukkeralf]

Iconic lavede aftale med Zymeworks i går og udlicensierede til Exelixis i dag. Igen vel en udløber af at tisotumab vedotin gør det godt

[saltpeter]

Jeg ved ikke helt om den er listet her,Bryan Garnier :GENMAB: SC Darzalex should make isatuximab obsolete | BUY | DKK1300(+17%)
GENMAB - BUY | DKK1300(+17%)
SC Darzalex should make isatuximab obsolete

Isatuximab’s data show no clear superiority over Dara
Subcutaneous Darzalex: a better Darzalex in every way

[saltpeter]

Just a moment...

(www.researchpool.com)

[E_L]

After discount row, NICE finally says yes to first line Revlimid https://www.pmlive.com/pharma_news/after_discount_row,_nice_finally_says_yes_to_first_line_revlimid_1288450

[E_L]

"The decision is a breakthrough for Celgene in England, where newer entrants – most notably Janssen’s Darzalex – are now making rapid in-roads."

[bongobob]

@gentogen efterlyste CD33xCD3 Duobody. Den er nævnt i J&J slides EL linkede til og nu også på Gemab produkt side JNJ-67571244. http://www.genmab.com/product-pipeline/products-in-development

[bongobob]

Vi er oppe på 6 stk. JJ duobody i klinikken!

[bongobob]

JNJ-63898081 er også ny for mig?

[E_L]

Also for me @bongobob @gentogen ! I was only aware of 4 of them, nice surprise!

[E_L]

JNJ-63898081 is in the clinic and recruiting already... prostate cancer https://clinicaltrials.gov/ct2/show/NCT03926013

[bongobob]

Yes in the JJ slides it is marked as undisclosed target CD3 bispecific

[E_L]

and the other one : A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) https://clinicaltrials.gov/ct2/show/NCT03915379